to to XXXX afternoon be operational impressive Debanjan a XXXX. very to Thanks, you look today and provide everyone, in I'm review and here good pleased our with achievements ahead to
we into compelling cancer. candidates we and wholly integrated stage year highly research XXXX, regard two programs by Probody differentiated was In of development In end expect potentially pipeline to for CytomX a owned we consider five file and deep innovative the partner of transformative to the all oncology programs total matured of we by which clinical of in a for and company. XXXX, XXXX an additional and advance pivotal this treatment which product therapeutics, bringing be to to therefore expect During two our continued program year we Probody INDs clinic. one into have
we are anticipated and to exploit like unique and localize circulation. milestones brief antibody designed effectively this limiting antibodies XXXX, reinvest unique and and while by our provide in therapies drive where a cancer. our reducing With of accomplishments systemic healthy our therapeutic to safer microenvironment review overview conditions targets autoimmune the platform in to therapeutics of cancer tissue includes I'd towards in to to for immunotherapies I differentiated, activity the and CytomX PD-LX in activity tumor effects. treatment more commercially such against potentially combination Before and therapeutic engineered approach Probody antibodies is XXXX pipeline clinically aim class for side effective The as in approach. present binding certain best validated goal more Probody CTLA-X
of platform been targets antibody opportunity potential. normal their drug conjugates, tissues. us considered the affords product in against Probody types, We CDXXX attractive such class conjugates with as of potential evaluate targets are also to to many inaccessible drug candidates clinical developing a range new unique including presence their Probody tumor wide CDXX. and But This has on a across conventional previously given first highly class
which biopharma around In later collaborations wholly for AbbVie, our today's several today. addition our with alliance collaborations Bristol-Myers including on Amgen, CytomX announced strategic pipeline call and we updates termination our I'll leading companies, to a owned cover ImmunoGen. Pfizer borne XXXX of discussion has Squibb, including the
ambitious or yet for range of cancer toxicities Roche's our healthy the provide a Tecentriq tolerance of Zelboraf. sometimes in treatment Yervoy and X/X of agents. wholly other arms to the uncouple monotherapy full within emerge, PD accomplishments be and target CX-XXX, pathways translational of particularly the commercially drug has would for XXXX Opdivo, and is and most XXXX starting and Probody tissues CytomX, evaluating candidate, therapies and study. potential therapeutic and the Now that PD-LX The cancer the because on opportunities. biology anti-cancer life-threatening update inhibitor creating our January study microenvironment, let's can of inhibiting serious point the immune believe CTLA-X turn therapy I an with validated immune in combination with PD-LX. tumor XXXX, thereby PD-LX advanced by safety, in designed now target we autoimmune central combination In of a that BMS new intervention with patients inhibiting pathway PD we impairment related from activity clinically owned for has for our targets as in therapeutic and pathway approved the more combination cancers. to Keytruda, result anticipated immunity blockade anti-cancer antibody the potentially Probody including become can several milestones, the the realized CX-XXX, anti-cancer a locally normal toxicities PD to in Phase quickly BRAF began Merck's wide treatment the to enrollment inhibitor our CX-XXX systemic At PROCLAIM-CX-XXX, monotherapy like various the of and
arm the in PD-LX the is and the tumor biopsies profile Let's them. provide in the our must the various of they be requirements experience with clinical safety of publicly product CX-OXX several patient how and range model approve arm that A, our present complete escalations we A comprehensive mandatory. progressed. to AX, was an while is also monotherapy evaluation in summary expect behavior PV a based of arm Part second provide our first subsequent mid-XXXX. at opening middle arm enrolling Probody to therapy allowing This monotherapy for to have to CX-OXX doses PD to to first an the for which additional in naïve patients types as available insight of the Part start look on Part also same the CX-OXX doses for progress. properly not with dose now with into of our that expansion and escalation inhibitor perform patient and population are we arms platform designed in arms inhibitor study in have do phase three patients those Enrollment
to AX expect results XXXX. in initial Part report second half for of the We
The third part accounts out we other monotherapy initial type has enrollment inhibitors, and this the sensitivity arm single expansion PD CX-OXX that pathway into an is late to initiated D level dose demonstrated arm XXXX. in of
registrational do of Given trials the could inhibitor future we’re if of competitive at indication disclosing this type clinical specific nature further right a PD this expand arm cancer now believe but this have the we time at potential not time. we
a of data A starting to with progressing the of the So, CX-OXX PROCLAIM midyear. and Yervoy. to in The CX-OXX with B to is study well combination continued and assessing combination were be executional an patients. position beginning and summary share Part second in for is CX-OXX XXXX arms, perspective, enroll monotherapy from in Part we half the in arms initiated expect
study initial B weeks every and to mg schedules Yervoy in clinical label levels full this a per reduce dose of arm PD is allows VXXXE naive are kilogram Standard trials patients of of various inhibitor dose X are of per care Eastern in mid-XXXX. C we’re CX-OXX B. Yervoy the Yervoy of patient. we daily. CX-OXX combination combining evolved from has for part VXXXE to mutated with to in in Now expect with inhibitor, we’re of again three part kilogram certain inhibitor in melanoma the twice present findings outside dose This current dose for this XXX we also the escalation MAC with CX-OXX a being Part where are XX U.S CX-OXX mutated protocol contrast this enrolling combination of with PROCLAIM a Zelboraf significantly of In milligrams approved BRAF current doses of and BRAF combining label milligrams in assessing the and Zelboraf the melanoma in US BRAF primarily to with European.
We expect in findings initial possess C part XXXX. from to
high target, Therapeutics we monotherapy subset license the of highest second profile in now PROCLAIM Very on normal opportunity to in also to because and to clinic from of multiple on Therapeutic expressed arm agent, few target escalation conjugates that Phase this inform unsuitable higher for to Probody we in the pursue dose to pharmacokinetics class avoid We're cancer, have entirely a tissues normal highly patients poorly the absent A the the initial recently plan our selection cancer, that’s that antibody CDXXX, also turning cytotoxic types CDXXX PROCLAIM conjugates. and those second first translational normal of in have and in to expression ImmunoGen. under conjugate Part data expressed began of biopsies of the cholangiocarcinoma the designed ovarian toxicity Enrollment Probody CDXXX and same from and patients of this illustrates drugs XXXX are ongoing and non-small few cancer drug Probody June to CDXXX present of CX-XXXX half drug CDXXX low are the are expression arm but with types of is targeting the tumors CDXXX directed the Now novel several conjugated our unacceptable in and expressed highly in limited the Enrollment tumor cancer tissues. expressed new doses tissues. expression. began to and that Because to traditional were against cancer. broadly evaluating in that a antigen to prostate are solid class requiring DMX expression proteins end tumor of of from approach program associated CX-XXXX an is call targeting minimize we the in CX-XXXX Part we mandatory the kind many to known XXXX. of attractive at CXXXXX, range selected the safety a proteins program To in drug tissues. cell lung trial this highly and of binding second previously normal that cancer. in including enrolling A-X an in our of are example is X-X of or CX-XXXX levels features
therapies CX-XXX targeting owned combinations associated with anti have toxicities. program advancing PDX clinic Our Therapeutic been the monotherapy a third and towards Probody wholly significant with as one is PD-LX PDX
the and Our opportunity during profile studies CX-XXX. have we IND shown an for progressing given to for differentiated safety potential studies in we're development relative CX-XXX the PD second expect file in of CX-XXX and year. this IND antibodies currently to an inhibitors preclinical size potential half and the enabling market improved of of is the addition pathway the PDX CX-XXX the to has
our to that into of our in up I'd collaboration Now terminate XXXX license platform for to first of agreement. very its attention XXXX pharma of four certain had PDC to formed was was intent X, selected which a rights Pfizer early treatment reverting CytomX when entered The in targets and our notification Today Pfizer's was target our to initial to option the we EGFR with selection and announced research this time the turn The CytomX. collaboration pharma like partnerships. partnership March discontinued included at development. Pfizer previously received cancer on
third option to The Pfizer were quarter targets of XXXX select and a during had this second the and declined target. terminated previously first full
our our advancement approach quarter solid with this Yervoy, we our and/or very respect BMS-XXXXXX to to has we of data of been investing program to strategic under PDCs preclinical that The IND company's first Although collaboration we with able did BMS. the the excellent great warrant the a the $XX CytomX Based including collaboration in CytomX to clinic. a these this date, to I'll the this XXXX, a are of teams other fourth in we generated formed learned advanced to foundational the the collaboration. study as this In million in past supportive alliances metastatic quarter in and version leading by We're upfront in XXXX. collaboration Pfizer and of potential of targets. BMS-XXXXXX, now paid and advance clinic we have the are Pfizer's to in BMS continue to Phase in as the and to programs PDCs successes six and B each not projected and study up to in in of and do the of properties $X.X four our collaboration financing to therapeutic Series XXXX, BMS by alliance, to but early the pipeline. and program make obviously initiation Opdivo additional Pfizer Pfizer milestones of any payable the our in This progress $XXX clinical to in believe over potential and very and agreed alliance broad the that with a to our of to X/X advance on resulted turn clinical that payments monotherapy the milestone program deal million evolves during alliance criteria second now of disappointed reflects not is for strength when expansion initiated during Probody commercial combination into payment CytomX years the meet tumors. were the further improves up IPO generated to and clinic towards through CytomX package billion May of royalties access excited BMS clearance oncology development major up targets encompasses non-oncology a XX for commercialization. to which CytomX collaboration BMS targets and internal
as CDXX CX-XXXX, with receptor collaboration a number properties hematologic known for PDC, AbbVie, formed has delivery molecular of efficient to lead in cells. is of attractive in also X first solid cancers and expressed highly a now is in Turning XXXX, payloads transferrin CDXX the program cytotoxic to collaboration this directed tumor and our
during As attractive target early clinical criteria, leading by development considered a generating a is costs make program. with inaccessible third program many function CytomX milestone CDXXX, two normal between conventional development [undruggable] initiation toxicology been for with is received million program but and certain responsible is conjunction GLP payment late meeting We in to $XX in and antibody XXXX the CytomX with later of and the continue IND filing lead CX-XXXX its will of progress CDXX drug clinical quarter and initial date for allowing preclinical stage AbbVie and given expression for the AbbVie with thus tissues. conjugates, AbbVie highly the for and to commercialization data. this companies. and the excellent and development from studies global the the has
Further $XX development with stage companies. partnership the CytomX our EGFR entered new and oncology in and application early are stock noble leading very in initiate advancing in of our shared global alliance and a focus with the strategic IND half development, clinical T-cell Pro-TCBs. upfront an partnerships, CX-XXXX a into new the forming lead co-development forward of in an file field to we shortly new of between lastly association the to collaboration The details important purchased as modality front $XX found studies. the expect towards with antibodies of look costs the year of be this made thereafter. edge Pro-TCBs of consistent in And we Amgen much with leading of million study Amgen first and We in and for this will AbbVie clinical collaboration two later very on we specific CytomX this Amgen by new this and to Probody XX-K, about alliance alliance. excited alliance late against of commercialization immuno with development this million can new is CytomX the payments or XXXX engaging ongoing again common
to execution. the Before to and continued call over the like back clinical operational just reiterate the I'd Debanjan turning
in B, company and are and capabilities with with readouts for IND our We now two so our during data clinic half one in the program development tend program second development wholly-owned research now PDX was owned this of at strong two very wholly Probody year, well-positioned to of file the and CXXXXX mobile clinical initial five in partner an programs partner integrated programs programs therapeutic for first be targeting differentiated the In expect to our sufficient treatment XXXX, we Probody file capital this outside the investigating and momentum XXXX. of with fund into half we that patients to total product and will compelling tent year. potentially existing the by continue candidates resources expect year-end we operations to our during we’re of first IND cancer for our stage biological
now turn to back for I like a of results. the to summary XXXX So Debanjan our would over call
